霍奇金淋巴瘤预后因素研究进展  

Progress of prognostic factors for Hodgkin lymphoma

作　　者：陶云霞 石远凯 Tao Yunxia;Shi Yuankai(Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs,Beijing 100021,China)

机构地区：[1]国家癌症中心,国家肿瘤临床医学研究中,国医学科学院北京协和医学院肿瘤医院内科,抗肿瘤分子靶向药物临床研究北京市重点实验室,北京100021

出　　处：《白血病．淋巴瘤》2021年第3期185-189,共5页Journal of Leukemia & Lymphoma

基　　金：国家重大新药创制科技重大专项(2012ZX09303012、2017ZX09304015)。

摘　　要：霍奇金淋巴瘤(HL)是一类可治愈性肿瘤。HL的治疗策略建立在分期及复发风险基础上。随着综合治疗模式不断优化,HL的预后得到极大改善。目前HL广泛使用的预后模型预测价值较前降低。因此,探索新的预后因素及丰富现有预后模型,为患者提供精准化及个体化治疗是HL重要的研究方向。文章就近年来HL预后因素研究进展进行综述。Hodgkin lymphoma(HL)is a type of curable tumor.The treatment strategy of HL is based on staging and risk of recurrence.With the continuous optimization of combined treatment mode,the prognosis of HL has been greatly improved.The predictive value of the prognostic models widely used in HL is lower than before.Therefore,exploring new prognostic factors and enriching existing prognostic models to provide patients with precise and individualized treatment is an important research direction for HL.This article reviews the progress of prognostic factors for HL in recent years.

关 键 词：霍奇金病 预后 分子生物学 

分 类 号：R733.1[医药卫生—肿瘤]